Product
Ambrisentan
Name
AMBRISENTAN
INN Name
ambrisentan
FDA Approved
Yes
5 clinical trials
8 organizations
9 indications
1 document
Indication
Hepatorenal syndromeIndication
CirrhosisIndication
Acute Kidney InjuryIndication
AscitesIndication
HypertensionIndication
PulmonaryIndication
COVID-19Indication
HypoxemiaClinical trial
A Multi-Centre, Randomised, Open-Label, Phase II Study of Ambrisentan in Patients With Hepatorenal SyndromeStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is DesiredStatus: Completed, Estimated PCD: 2022-06-09
Clinical trial
A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19Status: Terminated, Estimated PCD: 2023-02-27
Clinical trial
Individual and Combined Endothelin Receptor and SGLT1/2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter, Open-label Randomized Cross-over TrialStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)Status: Completed, Estimated PCD: 2022-06-01
Organization
Aurobindo Pharma LimitedDocument
DailyMed Label: AMBRISENTANOrganization
Sigmapharm Laboratories, LLCOrganization
Zydus Pharmaceuticals USA Inc.Organization
Quallent Pharmaceuticals Health LLCOrganization
Apotex Corp.Organization
Zydus Lifesciences LimitedOrganization
Cipla USA Inc.Organization
Sun Pharmaceutical Industries, Inc.